CSIMarket Company Name, Ticker, Suppliers, else..
 
Genenta Science S p a   (NASDAQ: GNTA)
 
Price: $0.7437 $0.00 0.364%
Day's High: $0.767799973487854 Week Perf: -11.57 %
Day's Low: $ 0.72 30 Day Perf: -36.44 %
Volume (M): 36,271 52 Wk High: $ 10.00
Volume (M$): $ 0 52 Wk Avg: $1.50
Open: $0.75 52 Wk Low: $0.55



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 7
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Genenta Science S.p.A. is a biotechnology company based in Milan, Italy. The company specializes in developing innovative gene therapies to treat various types of cancer. Genenta Science focuses on using a unique approach called Immune Reprogramming Gene Therapy (IRGT) to modify the patient's immune cells for targeted cancer treatment. IRGT involves modifying hematopoietic stem cells and reprogramming them to express specific genes that activate the immune system against cancer cells. This approach aims to enhance the body's ability to fight cancer and potentially offer new treatment options for patients. Genenta Science is dedicated to advancing the field of gene therapy and improving the lives of cancer patients.


   Company Address: Via dell’Annunciata No. 31 Milan 0
   Company Phone Number: 02.29.00.10.55   Stock Exchange / Ticker: NASDAQ GNTA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -0.3%    
ATRA   -3.94%    
BNTX        2.24% 
EXEL        1.11% 
GILD        3.46% 
KRYS   -2.36%    
• View Complete Report
   



Clinical Study

Genenta's Groundbreaking Reprogramming of Tumor Microenvironment Sets a New Course for Innovative Solid Tumor Treatments

Published Thu, Feb 8 2024 10:00 AM UTC

In recent years, scientific advancements in cancer treatment have focused on exploring innovative therapies that target the tumor microenvironment (TME), the complex network of cells and molecules surrounding the tumor. Genenta, a pioneering biopharmaceutical company, has recently demonstrated remarkable progress in reprogramming the TME in patients with glioblastoma multifo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 13.29
Working Capital Ratio 14.16
Leverage Ratio (MRQ) 0.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.37 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,044,772
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.